What is the ideal treatment for advanced non-small-cell lung cancer with PD-L1 level ≥50%? Is mono immunotherapy enough?

Future Oncol. 2024;20(38):3039-3041. doi: 10.1080/14796694.2024.2414731. Epub 2024 Nov 25.

Authors

Burak Bilgin¹, Sebnem Yucel¹, Mehmet Ali Nahit Sendur¹, Bulent Yalcin¹

Affiliation

¹ Ankara Yildirim Beyazit University, Ankara Bilkent City Hospital, Department of Medical Oncology, 06800, Ankara, Turkiye.

PMID: 39582298
DOI: 10.1080/14796694.2024.2414731

No abstract available

Keywords: PD-L1; atezolimuzmab; cemiblimab; chemotherapy; first line; immune-checkpoint inhibition; lung cancer; pembrolizumab.